A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Evaluation of Biomarkers in Subjects with Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Sponsor: Zeno Alpha, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS6670
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the effect of different doses of ZN-c5 on levels of hormone (estrogen) receptors in breast cancer and how large that effect is for each dose level. The amount of reduction in hormone receptors may indicate that the drug is doing what it intends to do and how effective it is. The results will help define what an effective dose will be for other patients in the future. The study will also further test the safety of the study drug at different dose levels.
This study is closed
Investigator
Katherine Crew, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
If you are female, are you postmenopausal? (If male, please select "yes.") Yes No
Have you been diagnosed with adenocarcinoma of the breast? Yes No
Do you have estrogen receptor-positive, HER2-negative breast cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE